Latest news

• Gilead plans fightback against HIV arch-rival ViiV

  The strong uptake of ViiV's drugs comes on the back of what is viewed as a superior profile for dolutegravir compared to Gilead's current integrase inhibitor elvitegravir - found in

• ViiV takes two-drug cocktail for first-line HIV into phase III

  and Gilead's Vitekta (elvitegravir) as well as simpler, single-tablet regimens, according to GlobalData. ... HIV therapies that combine multiple drugs into one tablet such as ViiV's Triumeq (dolutegravir/abacavir/lamivudine) and Gilead's Quad product

• Gilead gets EU nod for TAF-based triple therapy for HIV

  also bagged approval for four-drug Genvoya (elvitegravir, emtricitabine, cobicistat and TAF), an updated version of the company's $1.8bn Stribild brand. ... Bictegravir - an improved follow-up to elvitegravir - is currently in phase III trials in a single

• Gilead bags EU approval for next-generation HIV drug

  Four-drug product Genvoya (elvitegravir, emtricitabine, cobicistat and TAF) was approved in its first markets last year and is positioned to replace Gilead's $1.8bn Stribild brand.

• Rare disease therapies head the ‘class of 2015’

  Genvoya. HIV (in combination with cobicistat, emtricitabine and elvitegravir). nucleotide reverse transcriptase inhibitor.